Infectious Diseases

Infectious Diseases

infectiousdiseaseThere’s no room for uncertainty in identifying infectious diseases and finding effective treatment solutions. Success requires the confidence that can only come with the experience derived from clinical practice and the deep understanding gained from repeatedly navigating the complexities of infectious-disease research. This is the kind of confidence found at the DCRI. With an attentive network of key opinion leaders, site investigators, and faculty of practicing infectious-disease physicians, we stand ready with insights and innovative research methods needed to understand and defeat infectious diseases.

Visit the DCRI at the American Society for Microbiology (ASM) & Interscience Conference on Antimicrobial Agents and Chemotherapy.
Come to booth #2436 to learn more about the ARLG and how we are turning knowledge into clinical practice.

Meet Antibacterial Resistance Leadership Group (ARLG) Program Leader Heather Cross, DPhil, on Friday, June 2, from 12:30 p.m.–2:30 p.m., and Saturday, June 3, from 3:00 p.m.–5:00 p.m. Cross will be available to answer ARLG questions and conduct demos
of the Virtual Biorepository – Strain Catalogue.

Schedule a meeting at the booth for more information about
partnering with the DCRI Infectious Diseases team.

ASM 2017 | June 1–5, 2017

Ernest N. Morial Convention Center | 900 Convention Center Blvd. | New Orleans, LA 70130

In the past 10 years, our Infectious Diseases team has conducted more than 250 phase I–IV adaptive and multicenter trials throughout the world, as well as supported numerous prominent networks, registries, and other research projects. They have included:
  • Adult and pediatric vaccines
  • Complicated skin and skin structure infection
  • Duke Infection Control Outreach Network (DICON)
  • Emerging infections
  • Fungal infections: cryptococcus, aspergillus, candida
  • GI-related infections
  • HIV infection/AIDS
  • Hospital-acquired/ventilator-associated pneumonia
  • Hubert-Yeargan Center for Global Health
  • Infectious endocarditis
  • International Collaboration on Endocarditis (ICE)
  • NICHD Neonatal Research Network
  • Neonatal infectious diseases
  • Nosocomial infections
  • Pediatric infectious diseases
  • Staphylococcus aureus bacteremia
  • Staphylococcus Aureus Bacteremia Group (SABG): targeted clinical trials to reduce the risk of antimicrobial resistance
  • Transplant infections
  • Tuberculosis
landscape photo
Susanna Naggie, MD, MHS, Director, Infectious Diseases

Research Driven by the Needs of a Global Community

While infectious diseases can have distant origins, their impact is eventually felt locally, creating a critical need for a global response. The DCRI gets to work quickly through an integrated network of sites, investigators, and patient registries around the world. Aligned with a faculty of practicing infectious-disease physicians, we can provide unparalleled experience and efficiency in the design and coordination of infectious-disease trials.

Experienced and consistent Clinical Operations teams expertly manage all aspects of global clinical trials. Additionally, impeccable data integrity and biostatistical expertise yield credible study results that change clinical practice.

Program Highlights

ARLG: Combatting Antibacterial Resistance

In 2013, the DCRI was selected by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases to oversee a 6-year, $62 million grant that founded the Antibacterial Resistance Leadership Group (ARLG), a nationwide network dedicated to researching and combatting antibacterial resistance.

Now composed of 62 sites, the ARLG builds transformational trials aimed at changing clinical practice and reducing the impact of antibacterial resistance and antimicrobial resistance through strategies such as:

  • Early clinical evaluation of new antibacterials
  • Comparative effectiveness or efficacy trials
  • Strategy trials to optimize currently licensed antibacterials (dose, duration, need for drug) to reduce the risk of resistance
  • Clinical algorithm testing strategies
  • Treatment-based prevention measures
  • Diagnostics testing in the context of treatment trials, epidemiologic elements, or behavioral modification
  • Effective infection-control programs that include surveillance for resistant organisms, outbreak investigation, and antibiotic stewardship to prevent the development and spread of resistant organisms
  • Novel facilities-level activities to prevent the development of resistance
DICON: Controlling Hospital-Borne Infections

The Duke Infection Control Outreach Network (DICON) is part of DCRI’s Infectious Disease group. It is a consortium of 43 hospitals and outpatient surgery centers in five states, ranging from small community hospitals to large regional medical centers. Additionally, it has 9,000 occupied beds and 45,000 employees.

DICON provides its members with sophisticated data analysis and metrics, access to experts in infection control, opportunities to share successful programs, and extensive educational initiatives related to infection prevention. The network has amassed a database of more than one million surgical procedures and more than 17.2 million patient-days of demographic, treatment, and outcomes information.

A wealth of data has been made available by DICON to speed and improve trial design. The consortium has had significant and substantial impact on reducing the risk of postsurgical, device-related, and bloodstream infections, as well as helping to reduce the risk of blood and body-fluid exposures for employees in DICON-affiliated hospitals.

SABG and ICE: Monitoring Staphylococcus Aureus and Endocarditis

Our Infectious Disease division taps into the wealth of data held by the Staphylococcus Aureus Bacteremia Group (SABG) and the International Collaboration on Endocarditis (ICE), both headquartered at the DCRI. SABG has the largest collection of S. aureus bacteremia outcomes data in the world, with more than 1,300 patients in the registry and 12 weeks of follow-up that includes genetic fingerprinting.

ICE is the most extensive registry of infective endocarditis in the world, composed of 1,600 patients enrolled in the prospective registry and another 3,000 in a retrospective database. The registry collects extensive outcomes data, including ECG and serology core laboratory analyses.

The DCRI Infectious Diseases Faculty

Our faculty members see the devastation and human cost of infectious diseases every day in the faces of the patients they treat. Our track record of successful partnerships with industry, government, and academia is unparalleled. Appointed faculty members within the DCRI have advanced degrees in epidemiology, statistics, ethics, and regulatory compliance, as well as expertise across key infectious diseases areas.

Infectious Diseases Leadership at the DCRI

Susanna Naggie, MD, MHS, Director

susanna-naggie-newsSusanna Naggie, MD, MHS, is an infectious diseases specialist and assistant professor of medicine at Duke University Medical Center. Her primary research interest is the care of HIV/HCV co-infected individuals.

She is responsible for two multidisciplinary HIV/HCV co-infection clinics, one at Duke University and one at the Durham VA Medical Center. She is currently the principal investigator on several clinical trials of direct-acting antivirals for the treatment of HCV in HIV-infected patients. She also serves as virologic and medical monitor for clinical trials for the treatment of HCV at the DCRI. She currently serves as co-chair of the International Antiviral Society-USA’s Viral Hepatitis Committee and is a member of the American Association for the Study of Liver Disease, the Infectious Diseases Society of America, and the International AIDS Society.

She received her bachelor’s degree from the University of Maryland and her medical degree from Johns Hopkins University. She also received a master’s of health sciences degree from Duke.

DCRI Infectious Disease Faculty